← All trials
NCT06475742
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2024
- Primary completion
- Nov 30, 2027
- Completion date
- May 31, 2028
- First posted
- Jun 26, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 680
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Idorsia Pharmaceuticals Ltd.Lead sponsor
- Idorsia Pharmaceuticals Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.